JD Health International Crescita futura

Future criteri di controllo 3/6

JD Health International prevede che gli utili e i ricavi cresceranno rispettivamente di 14.6% e 10.5% all'anno. Si prevede che l'EPS crescerà di 14.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 7.7% in 3 anni.

Informazioni chiave

14.6%

Tasso di crescita degli utili

14.1%

Tasso di crescita dell'EPS

Consumer Retailing crescita degli utili	29.4%
Tasso di crescita dei ricavi	10.5%
Rendimento futuro del capitale proprio	7.7%
Copertura analitica	Good
Ultimo aggiornamento	28 Nov 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

SHSC:6618 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	72,321	3,902	7,946	7,122	17
12/31/2025	64,844	3,550	6,757	5,556	19
12/31/2024	57,729	3,109	5,220	4,557	19
6/30/2024	54,764	2,618	6,436	6,467	N/A
3/31/2024	54,147	2,380	5,490	5,536	N/A
12/31/2023	53,530	2,142	4,544	4,605	N/A
9/30/2023	53,576	1,930	3,135	4,311	N/A
6/30/2023	53,621	1,718	1,726	4,017	N/A
3/31/2023	50,179	1,049	2,679	4,961	N/A
12/31/2022	46,736	380	3,632	5,905	N/A
9/30/2022	42,003	-7	3,440	4,829	N/A
6/30/2022	37,270	-395	3,249	3,753	N/A
3/31/2022	33,976	-734	3,085	3,592	N/A
12/31/2021	30,682	-1,074	2,921	3,431	N/A
9/30/2021	27,463	-6,702	4,068	4,352	N/A
6/30/2021	24,243	-12,331	5,216	5,274	N/A
3/31/2021	21,813	-14,783	4,439	4,487	N/A
12/31/2020	19,383	-17,234	3,662	3,699	N/A
9/30/2020	17,007	-11,901	1,980	2,004	N/A
6/30/2020	14,631	-6,567	298	309	N/A
3/31/2020	12,737	-3,769	351	359	N/A
12/31/2019	10,842	-972	404	409	N/A
12/31/2018	8,169	215	185	187	N/A
12/31/2017	5,553	179	N/A	36	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 6618 ( 14.6% all'anno) è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Si prevede che gli utili di 6618 ( 14.6% all'anno) cresceranno più rapidamente del mercato Hong Kong ( 11.5% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 6618 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 6618 ( 10.5% all'anno) crescerà più rapidamente del mercato Hong Kong ( 7.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 6618 ( 10.5% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 6618 sarà basso tra 3 anni ( 7.7 %).

JD Health International Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Investor sentiment deteriorates as stock falls 17%

Insufficient new directors

Now 22% overvalued after recent price rise

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.50 in 1H 2023)

JD Health International Inc. Announces Appointment of Professor George Lau as Independent Non-Executive Director

JD Health International Inc. to Report First Half, 2024 Results on Aug 15, 2024

Now 23% undervalued after recent price drop

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc., Annual General Meeting, Jun 21, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc. to Report Q4, 2023 Results on Mar 20, 2024

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 18%

First half 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.072 in 1H 2022)

JD Health International Inc. to Report First Half, 2023 Results on Aug 16, 2023

Now 23% undervalued

Independent Non-Executive Director recently sold HK$108k worth of stock

JD Health International Inc. Announces Chief Financial Officer Changes

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.35 loss in FY 2021)

CEO & Executive Director recently sold HK$5.1m worth of stock

Independent Non-Executive Director recently sold HK$55k worth of stock

First half 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.15 loss in 1H 2021)

JD Health International Inc. to Report First Half, 2022 Results on Aug 23, 2022

Chairman recently sold HK$195m worth of stock

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

JD Health International Inc. Announces Board Changes

JD Health International Inc. (SEHK:6618) announces an Equity Buyback for HKD 3,000 million worth of its shares.

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

Independent Non-Executive Director recently sold HK$61k worth of stock

Non-Executive Director Pang Zhang has left the company

First half 2021 earnings released: CN¥0.15 loss per share (vs CN¥2.49 loss in 1H 2020)

Full year 2020 earnings released: CN¥7.80 loss per share (vs CN¥0.45 loss in FY 2019)

Non-Executive Director has left the company

Independent Non-Executive Director has left the company

Full year 2020 earnings released: CN¥7.80 loss per share

JD Health International Inc. to Report Fiscal Year 2020 Results on Mar 29, 2021

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita